Aurobindo Pharma Transfers Domestic Branded Generic Business to Auropharm Limited

Aurobindo Pharma has completed the transfer of its domestic branded generic pharmaceutical formulations products business to its wholly owned subsidiary, Auropharm Limited. The transfer was executed on a slump sale basis and became effective on July 1, 2026. This strategic realignment consolidates the domestic operations within the subsidiary entity.

The completion follows the execution of a Business Transfer Agreement (BTA) between Aurobindo Pharma and Auropharm Limited, formerly known as Auro Pharma Limited. The company had initially informed the exchanges regarding this agreement on April 6, 2026. The transaction adheres to the terms outlined in the BTA and complies with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Key Transaction Details

The following table summarizes the primary details of the business transfer:

Aspect:	Details
Transferor	Aurobindo Pharma Limited
Transferee	Auropharm Limited (Wholly Owned Subsidiary)
Business Transferred	Domestic branded generic pharmaceutical formulations products business
Nature of Transfer	Slump sale (as a going concern)
Effective Date	July 1, 2026

With the completion of this transfer, the domestic branded generic business is now being undertaken by Auropharm Limited. The company confirmed that all necessary conditions required for the transfer have been fulfilled.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+0.54%	+1.99%	+8.88%	+30.85%	+37.84%	+61.25%

Aurobindo Pharma USA Inc, a wholly owned subsidiary of Aurobindo Pharma Limited, has completed the acquisition of Lannett Company, Inc., USA. The transaction received approval from the U.S. Federal Trade Commission on June 18, 2026, concluding the purchase from Lannett Seller Holdco, Inc.

Effective June 29, 2026, Lannett has become a wholly owned subsidiary of Aurobindo Pharma USA Inc and will operate as Lannett Company LLC. The integration process has commenced immediately, with a focus on ensuring uninterrupted access to critical medications and maintaining relationships with partners.

The acquisition adds more than 400 Lannett employees to the organization, strengthening its talent base and operational capabilities. The company aims to combine resources to enhance the availability of essential medicines and deliver long-term value to patients and stakeholders.

Aurobindo Pharma Limited acknowledged the leadership of Lannett's management team for their role in enabling a smooth transition. The disclosure was made to the National Stock Exchange of India Limited and BSE Limited under Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015.